Compare DexCom, Inc. (DXCM) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Prospect Capital Corporation — how do they compare? DexCom, Inc. trades at $77.8 (market cap $28.06B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: DexCom, Inc. is far larger — about 24.6× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PSEC | |
|---|---|---|
Market Cap | $28.06B | $1.14B |
Sector | Health | Financials |
52-Week High | $89.53 | $3.47 |
52-Week Low | $54.84 | $2.15 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Prospect Capital Corporation (PSEC) trades at $2.27, showing modest daily gains of 0.89%. The stock presents a mixed picture with a deeply discounted price-to-book ratio of 0.39 and consistent recent earnings beats, but faces significant fundamental challenges including negative revenue of -$407M for 2025 and a net income margin of -495.94%. Recent business activity includes the successful sale of Valley Electric for $328M and new investments in ShipOffers, while technical indicators signal a bearish trend with moving averages pointing downward.
The outlook for PSEC is cautious despite its attractive dividend yield and deep NAV discount. Investment opportunity exists in the substantial 59-63% discount to net asset value and 18%+ yield, but risks are elevated due to persistent negative revenue trends, declining NAV, dividend cuts, and mixed analyst sentiment with only 25% buy ratings. Shareholders face ongoing portfolio quality concerns and management execution challenges in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
